News at CenExel

Advancements in Vaccines: Bridging the Past and Future

    Advancements in Vaccines: Bridging the Past and Future - by Nelia Sanchez-Crespo, MD The history of vaccines is a testament to the incredible progress we've made in protecting humanity against infectious diseases. From the invention of the smallpox...

Understanding Alzheimer’s Disease: Recognizing Warning Signs

Understanding Alzheimer's Disease: Recognizing Warning Signs - by Sanjiv Sharma, MD, CPI Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide. It's the most common cause of dementia among older adults and presents a...

FDA Approves ABRYSVO for RSV

In the last week, the FDA approved the first maternal vaccine designed to safeguard infants from respiratory syncytial virus (RSV) during the critical period immediately from birth up to 6 months of age, when they are most vulnerable to infection. RSV, a highly...

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

CenExel is proud to announce the publication of the work of Kimball A. Johnson, MD, from CenExel iResearch, in the New England Journal of Medicine. Dr. Johnson participated in a study of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age. Other contributors included Evan J. Anderson, MD, C. Buddy Creech, MD, MPH, Vlasimir Berthaud, MD, MPH, Arin Piramzadian, DO, et al., for the KidCOVE Study Froup*